Hemnabh Varia

Andy Davis is a principal for Deloitte Consulting LLP’s Health Care practice, with over 15 years of experience as a leader in our health actuarial practice, driving change across the ecosystem with payers, providers, and life sciences companies. He is known for bringing an understanding of how to quantify the economic value of services to members, patients, and customers, which spans payers, providers, PBMs, large pharmaceutical manufacturers, medtech, and diagnostics companies.

Andy Davis is a principal for Deloitte Consulting LLP’s Health Care practice, with over 15 years of experience as a leader in our health actuarial practice, driving change across the ecosystem with payers, providers, and life sciences companies. He is known for bringing an understanding of how to quantify the economic value of services to members, patients, and customers, which spans payers, providers, PBMs, large pharmaceutical manufacturers, medtech, and diagnostics companies.

Diagnostics industry leaders are taking note of major market forces, including pressure from payers to reduce costs and improve patient outcomes, changing patient, consumer, and provider behaviors, and real-world learnings from the COVID-19 pandemic. These forces are contributing to the birth of a new health care delivery system—one in which the focus will likely shift from reactionary, treatment-based care to prevention and well-being.